<img src="https://ml-eu.globenewswire.com/Resource/Download/f164672f-d67c-41d2-9c79-46caee419077?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Logo_Pharming_original.png" alt="Pharming Group N.V."/>Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration: <a href="https://www.globenewswire.com/Tracker?data=cOOzYQWoS3HH19vCF1nvxRLoIYqwdh_X_iVNYMqB-eRpUhHStIl3jS9LiPmkvT2Lg3maQQmvN1P6FjtGiosmtgLUzc5fgy122bZ3-x9rSszR8qq4p5KecyiWyV3g9ccRiJJzyMAduzbOT3rynY9VVjnLGxvNjJqWkXInOo0RHF4erEcOW2lxwviLePEQhzIjZ678jbHluTU7MIXcyrTlDl5v6oXoczTjCEvnPe7ZXpUaWa-MNfDwPpTkuQN4xxb28pF2NFkbWBRXxwQfk-NwrQ==" rel="nofollow" target="_blank" title="">https://register-conf.media-server.com/register/BId285845cff504c39931913d279f646ea</a> Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Please note, the Company will only take questions from dial-in attendees. Webcast registration: <a href="https://www.globenewswire.com/Tracker?data=cOOzYQWoS3HH19vCF1nvxXH7u5YCIh_SoNITenq6GEjekYA9zbqQTs4_Ui-sHGlGsuuSeWBYnyFke8D5R3Wa441nRC45SsRdgaRqlB7P55ZTsuWyj8Ke4XDjFcBBtYBNrleqbQANmvcp19yrLNtV1j1tTgIX9nsfo87SPS_M_jg=" rel="nofollow" target="_blank" title="">https://edge.media-server.com/mmc/p/m35zejc7</a> The webcast will also be accessible on the Pharming website at <a href="https://www.globenewswire.com/Tracker?data=7IY9LZtsOXBaGe8P8X5bDvzAQEOKj-zj6aLw2-qD8GCFQ8FriKNzVg9urTNiFDblB06mjm9QdHxh8EBLcLAwwB6pGMLfFEkG2dhLcWUzc4YmjHcVdArmaZpcnFjw1_2PQThfUCcYXzrYzT0Rke6fz7dB7ZUfbAa_hbsRS1U_5-MX2JhmnZITiSDvOUPTM8A78HbGQZjEDviKzkRXdFmzlQ==" rel="nofollow" target="_blank" title="Investors/Financial Documents &amp; Reports">Investors/Financial Documents &amp; Reports</a>, and a replay will be available shortly after the event. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=h8Xif_-84_Ss6r-LaNKC4IIwX-HoF-nnkjgV-FUeoQqqYcQ-nxUW3UOvlKZiZxJNDhWnbps93CiGeJNAw6cc2XJxCPd-fTRVTMRZaqgQkEQ=" rel="nofollow" target="_blank" title="www.pharming.com">www.pharming.com</a> and find us on <a href="https://www.globenewswire.com/Tracker?data=DRYAOMFXHmO6m8r-6H-PTW9zI5sCdn9FFnkOvmfrRUxKHzrc6mDQpxP2u2_vJ4JPUsfSSkSWf0gp87SeH2mDziwoqmYC110DbkMnV_t6jZg=" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>. For further public information, contact: Pharming Michael Levitan, VP Investor Relations and Capital Markets T: +1 (908) 705 1696 E: <a href="https://www.globenewswire.com/Tracker?data=7c8UneSCX2bx_NxmOz40lE6zxh1HEtPMRhCQMdQ8imB4ikEWaJfC7Cfk883ke1E3L7ANL5f-bH2HlJUdPVjXGB1L-6md6OIxETdFfDuPeQ4=" rel="nofollow" target="_blank" title="">investor@pharming.com</a> Saskia Mehring, Head of Corporate Communications T: +31 6 28 32 60 41 E: <a href="https://www.globenewswire.com/Tracker?data=74a1aINyJX_qjhHIEYsizcb4hgzdnEDucBhLokYJnsgycWLkF9PfSG3o9aWLPOkHShP6YcG5PbzPD0D5OIcQA6EdKf_mlgPaD2Vkh2P6olIfMlFh4JnfKacjkxN2OlzP" rel="nofollow" target="_blank" title="media.relations@pharming.com">media.relations@pharming.com</a> Media Relations Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming) E: <a href="https://www.globenewswire.com/Tracker?data=aJ4sUANSzWLPwGhDGIi7b2OE3C7Z8d1v8NcQKK-hwiMqG2tn_WbjDQJmMxr_qaWBWEWg9XyEqPMO5NRq7wrwDLlVs9Wu68tOQ2--B1fT5FbooSCsYuhNLngJsYt5YXUh" rel="nofollow" target="_blank" title="jdeutsch@lyraadvisory.com">jdeutsch@lyraadvisory.com</a> Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T: +31 6 53 81 64 27 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MBTxJs_skKIOeZ2sk5lrPJr0mK5Nu8KbdWs-yrsaietejDCLCjrFfa3i3mJzfIWPhNUxVotNzl8ifb0jmjX4oonVChSXPTyUistmhyaQPwlNBz-wmqb9ZyScLt99umH9ojKrYdtp9uBhJrk2W_nKCEgTAGdoXYCxP_1rFQLxPM6Of8ZquO5_qLcAjxP4UUaxW9G2X-21I0w99sDCfm3YB7Dw76SR1r9wBAoLjY4VX_o=" title="Pharming Group to report 2Q_1H26 results_EN_16JULY2026" rel="nofollow">Pharming Group to report 2Q_1H26 results_EN_16JULY2026</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/ZTNkODIxOWItZDExNy00ZWFjLThiMjQtZmUzNmU5ZjdlOGNkLTEwMTI1NDktMjAyNi0wNy0xNi1lbg==/tiny/Pharming-Group-N-V-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn